Add a DPP-4 Inhibitor to Your Current Regimen
For a patient with type 2 diabetes inadequately controlled on metformin 1000 mg twice daily and empagliflozin 25 mg daily, adding a DPP-4 inhibitor is a reasonable oral medication option to further improve glycemic control. 1
Rationale for DPP-4 Inhibitor Addition
The 2022 ADA/KDIGO consensus explicitly addresses this scenario, stating that when additional glucose-lowering agents are needed beyond metformin and SGLT2 inhibitors, DPP-4 inhibitors are appropriate oral options 1. DPP-4 inhibitors have moderate glucose-lowering efficacy (HbA1c reduction of approximately 0.5-0.8%), are weight-neutral, and carry minimal hypoglycemia risk when used without sulfonylureas 2.
Recent clinical trial evidence directly supports this approach: A 2026 phase 3 trial demonstrated that adding anagliptin (a DPP-4 inhibitor) to metformin plus empagliflozin 25 mg resulted in significant HbA1c reduction of -0.80% compared to placebo (P < 0.0001) at 24 weeks, with improved beta-cell function and no severe hypoglycemia 3. Similarly, a 2026 Korean study showed empagliflozin added to metformin plus sitagliptin reduced HbA1c by -0.7% to -0.8% 4.
Specific DPP-4 Inhibitor Recommendations
Choose based on renal function 1:
- Linagliptin: No dose adjustment needed regardless of eGFR—the preferred choice if renal function is uncertain or declining
- Sitagliptin: Standard dose if eGFR ≥45; reduce to 50 mg daily if eGFR 30-44; reduce to 25 mg daily if eGFR 15-29
- Saxagliptin or Alogliptin: Require dose adjustments at lower eGFR thresholds
Alternative Consideration: GLP-1 Receptor Agonist
If the patient has cardiovascular disease, chronic kidney disease, or needs more potent glucose-lowering with weight loss, prioritize adding a GLP-1 receptor agonist instead of a DPP-4 inhibitor 1, 5, 6. The 2025 ADA Standards recommend GLP-1 RAs as the preferred injectable option when additional therapy is needed, particularly for patients with:
- Established ASCVD or high cardiovascular risk
- eGFR 25-60 mL/min/1.73 m² (use dulaglutide, liraglutide, or semaglutide—no dose adjustment required) 1
- Need for greater HbA1c reduction (1.0-2.0% vs. 0.5-0.8% with DPP-4 inhibitors)
However, GLP-1 RAs require subcutaneous injection, which may not align with the patient's preference for oral therapy. The 2024 ACP guideline gives strong support to adding either SGLT2 inhibitors or GLP-1 agonists to metformin for mortality and morbidity benefits, but notes that oral semaglutide is now available as an alternative 6.
What NOT to Do
Do not combine a DPP-4 inhibitor with a GLP-1 RA 5—there is no additional glucose-lowering benefit beyond the GLP-1 RA alone, making this combination wasteful and potentially increasing side effects.
Avoid sulfonylureas as the next step unless cost is prohibitive. While they effectively lower glucose, they increase hypoglycemia risk and cause weight gain 2, 7. The 2018 ADA/EASD consensus notes sulfonylureas have high glucose-lowering efficacy but significant downsides 2.
Monitoring and Dose Adjustments
When adding a DPP-4 inhibitor:
- Reassess HbA1c in 3 months to evaluate response
- No need to reduce metformin or empagliflozin doses—DPP-4 inhibitors do not increase hypoglycemia risk with these agents 2
- Monitor for rare adverse effects: pancreatitis (very rare), musculoskeletal symptoms 2
- Check renal function if not recently done to guide DPP-4 inhibitor selection and dosing 1
Common Pitfall to Avoid
The most common error is therapeutic inertia—delaying intensification when glycemic targets are not met. The 2025 ADA Standards emphasize that treatment intensification should not be delayed when patients are not meeting individualized goals 5. If HbA1c is ≥1.5% above target, consider dual-combination therapy or more potent agents immediately 5.